Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S
Department of Dermatology, Tor Vergata University of Rome, Italy.
J Dermatolog Treat. 2004 Jan;15(1):23-6. doi: 10.1080/09546630310019346.
Psoriasis is a common, chronic, cell-mediated, inflammatory skin disease. Treatment limitations and a developing understanding of its pathogenesis on a molecular level have encouraged much interest in the field of immunomodulatory therapy.
To evaluate the efficacy and safety of fumaric acid esters, in particular dimethylfumarate (DMF), in the treatment of moderate to severe plaque psoriasis intolerant and/or resistant to other conventional systemic therapies.
A total of 40 patients were enrolled in this study. DMF was orally administered at the daily dose of 30 mg up to 360 mg for a minimum of 6 months treatment. Patients were followed-up with psoriasis area and severity index (PASI) score assessment, and clinical and photographic documentation.
A total of 33 (82.5%) patients achieved complete clinical remission with DMF treatment: eight after 3 months and 25 after 6 months. Adverse events, such as intolerable abdominal cramps and incoercible diarrhoea, occurred in four patients who, for this reason, interrupted therapy.
The findings suggest that DMF is a safe, effective and well-tolerated long-term oral treatment worthy of consideration for selective patients.
银屑病是一种常见的慢性细胞介导的炎症性皮肤病。治疗局限性以及对其分子水平发病机制认识的不断发展，激发了人们对免疫调节治疗领域的浓厚兴趣。
评估富马酸酯，特别是富马酸二甲酯（DMF），治疗对其他传统全身治疗不耐受和/或耐药的中度至重度斑块状银屑病的疗效和安全性。
本研究共纳入40例患者。DMF口服给药，每日剂量30mg，最大剂量360mg，治疗至少6个月。对患者进行随访，评估银屑病面积和严重程度指数（PASI）评分，并进行临床和照片记录。
共有33例（82.5%）患者接受DMF治疗后实现完全临床缓解：3个月后8例，6个月后25例。4例患者出现了难以忍受的腹部绞痛和无法控制的腹泻等不良事件，因此中断了治疗。
研究结果表明，DMF是一种安全、有效且耐受性良好的长期口服治疗方法，值得部分患者考虑。
Zotero 插件